natgillin/translations-raw huggingface dataset:
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Učestalost nuspojava u nastavku teksta definira se na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 do < 1/10); manje često (≥ 1/1.000 do < 1/100); rijetko (≥ 1/10.000 do < 1/1.000); vrlo rijetko (< 1/10.000).
The frequency of adverse reactions listed below is defined using the following convention: very common ( 1/10); common ( 1/100 to < 1/10); uncommon ( 1/1,000 to < 1/100); rare ( 1/10,000 to
Učestalost dolje navedenih nuspojava definirana je na sljedeći način: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do
The frequency of adverse reactions listed in Table 1 is defined using the following convention:
Učestalost nuspojava navedenih u tablici 1 definirana je pomoću sljedećih razreda:
The frequency of adverse reactions of prolonged-release exenatide identified from clinical trials and spontaneous reports (not observed in clinical trials, frequency not known) are summarised in Table 1 below.
U Tablici 1 u nastavku sažeto su prikazane učestalosti nuspojava eksenatida s produljenim oslobađanjem prikupljene iz kliničkih ispitivanja i spontanih prijava (nisu zamijećene u kliničkim ispitivanjima, učestalost je nepoznata).
The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports.
a Učestalost nuspojava prijavljenih tijekom primjene nakon stavljanja lijeka u promet ne može se odrediti budući da su izvedene iz spontanih prijava.
The frequency of all of the adverse reactions in vascular surgery was uncommon (defined as > 1/1000, < 1/100).
Pri vaskularnim kirurškim zahvatima učestalost svih nuspojava bila je manje česta (definirano kao (≥1/1 000 <1/100).
The frequency of anti-dsDNA antibodies at 1 year of follow-up in patients anti-dsDNA negative at baseline was uncommon.
Bolesnici koji su na početku bili negativni na anti-dsDNK antitijela, učestalost zabilježenih pozitivnih nalaza na anti-dsDNK nakon godinu dana praćenja iznosila je 1,1%.
The frequency of anti-dsDNA antibodies at 1 year of follow-up in patients anti-dsDNA negative at baseline was uncommon.
U bolesnika koji su na početku bili negativni na anti-dsDNK antitijela, učestalost zabilježenih pozitivnih nalaza na anti-dsDNK nakon godinu dana praćenja iznosila je 1,1%.
The frequency of anti-vedolizumab antibody detected in patients 16 weeks after the last dose of vedolizumab (approximately five half-lives after the last dose) was approximately 10% in GEMINI I and II.
Učestalost anti-vedolizumab protutijela detektiranih u bolesnika 16 tjedana nakon posljednje doze vedolizumaba (približno pet poluživota nakon posljednje doze) iznosila je oko 10% u ispitivanjima GEMINI I i II.
The frequency of ARs during post marketing only is considered as “not known (cannot be estimated from the available data)”.
Učestalost nuspojava nakon stavljanja lijeka na tržište okarakterizirana je kao "nepoznato (ne može se procijeniti iz dostupnih podataka)".
The frequency of arterial thromboembolic events was comparable between the two treatment arms in the phase 3 study 1199.13 (LUME-Lung 1).
Učestalost arterijskih tromboembolijskih događaja bila je usporediva između dvije liječene skupine u fazi 3 ispitivanja 1199.13 (LUME-Lung 1).
The frequency of azoospermia and oligospermia in the SmPC/PL should be changed from “very rare” to “very common”.
Učestalost azoospermije i oligospermije u Sažetku opisa svojstava lijeka/Uputi o lijeku potrebno je promijeniti iz “vrlo rijetko” u “vrlo često”.
The frequency of both of these effects was uncommon (may affect up to 1 in 100 people).
Učestalost ove obje nuspojave bila je manje česta (mogu se javiti u do 1 na 100 osoba).
The frequency of congenital malformations was 4 (5%) for Levemir and 11 (7%) for NPH with 3 (4%) major malformations for Levemir and 3 (2%) for NPH.
Učestalost prirođenih malformacija iznosila je 4 (5%) uz Levemir i 11 (7%) uz NPH, sa 3 (4%) teške malformacije uz Levemir i 3 (2%) uz NPH.
The frequency of gastrointestinal perforation was comparable between the treatment arms in the clinical study.
Učestalost gastrointestinalne perforacije je bila usporediva između liječenih skupina u kliničkoj studiji.
The frequency of GI-vaginal fistulae in the group treated with Avastin + chemotherapy was higher in patients with recurrence within the field of prior radiation (16.7%) compared with patients with recurrence outside the field of prior radiation (3.6%).
Učestalost gastrointestinalno-vaginalnih fistula u skupini liječenoj lijekom Avastin + kemoterapijom bila je viša u bolesnica s recidivom unutar područja koje je prethodno bilo zračeno (16,7%) nego u onih s recidivom izvan područja koje je prethodno bilo zračeno (3,6%).
The frequency of Grade 3 or 4 thrombocytopenia, neutropenia, and anaemia was higher in patients with AP-CML and BP-CML/Ph+ ALL than in patients with CP-CML (see Table 5).
Učestalost stupnja 3 ili 4 trombocitopenije, neutropenije i anemije bila je viša u bolesnika s AP-KML i BP-KML/Ph+ ALL nego u bolesnika s CP-KML (vidjeti Tablicu 5).
The frequency of grade 3-4 events was similar for patients treated with Jakavi or reference treatments (4.7% versus 3.1%).
Učestalost događaja stupnja 3-4 bila je slična za bolesnike liječene Jakavijem ili referentnim terapijama (4,7% u odnosu na 3,1%).
The frequency of hypoglycaemia depended on the background therapy in the respective studies.
Učestalost hipoglikemije ovisila je o osnovnoj terapiji u odgovarajućim ispitivanjima.
The frequency of hypoglycaemia depended on the background therapy in the respective studies.
Učestalost hipoglikemije ovisila je o osnovnom liječenju u odgovarajućim ispitivanjima.
The frequency of IARs decreased over time.
Učestalost reakcija povezanih s infuzijom smanjila se s vremenom.
The frequency of inhibitors observed in these studies is within the expected range.
Učestalost inhibitora opaženih u ovim ispitivanjima unutar je očekivanog raspona.
The frequency of nausea and diarrhoea was ‘Common’ for Xultophy and ‘Very common’ for liraglutide.
Učestalost mučnine i proljeva bila je ‘često’ za Xultophy i ‘vrlo često’ za liraglutid.
The frequency of notable QTcF intervals [i.e. >450 ms (males) and >470 ms (females)] and reports of hypokalaemia were similar to placebo.
Učestalost upadljivih QTcF intervala [tj. >450 ms (muškarci) i >470 ms (žene)] i hipokalijemije bila je slična kao za placebo.
The frequency of patients with hypoglycaemic events was similar for empagliflozin and placebo as add-on to metformin, and for the combination of empagliflozin with metformin in drug-naïve patients compared to those treated with empagliflozin and metformin as individual components.
Učestalost bolesnika s hipoglikemijskim događajima bila je slična uz empagliflozin i placebo kao dodatkom metforminu, te u prethodno neliječenih bolesnika koji su primali kombinaciju empagliflozina i metformina u usporedbi s bolesnicima liječenim empagliflozinom i metforminom kao pojedinačnim komponentama.
The frequency of patients with major hypoglycaemic events was low (<1%) and similar for empagliflozin and placebo as add-on to metformin, and for the combination of empagliflozin with metformin in drug-naïve patients compared to those treated with empagliflozin and metformin as individual components.
Učestalost bolesnika s događajima teške hipoglikemije bila je niska (< 1 %) i slična uz empagliflozin i placebo kao dodatkom metforminu, te u prethodno neliječenih bolesnika koji su primali kombinaciju empagliflozina i metformina u usporedbi s bolesnicima liječenim empagliflozinom i metforminom kao pojedinačnim komponentama.
The frequency of patients with minor hypoglycaemia was similar for empagliflozin and placebo as monotherapy, add-on to metformin, add-on to pioglitazone with or without metformin, and for the combination of empagliflozin with metformin in drug-naïve patients compared to those treated with empagliflozin and metformin as individual components.
Učestalost blage hipoglikemije u bolesnika bila je slična u skupinama koje su primale empagliflozin i placebo u obliku monoterapije, kao dodatak metforminu, kao dodatak pioglitazonu sa ili bez metformina, te u prethodno neliječenih bolesnika koji su primali kombinaciju empagliflozina i metformina u usporedbi s bolesnicima liječenim empagliflozinom i metforminom kao pojedinačnim komponentama.
The frequency of PML in B- CLL patients treated with alemtuzumab is no greater than the background frequency.
Učestalost PML-a u bolesnika s B-KLL-om liječenih alemtuzumabom nije veća od osnovne učestalosti.
The frequency of possible adverse effects is defined using the following convention:
Učestalost nuspojava je definirana sukladno sljedećim pravilima:
The frequency of possible adverse effects is defined using the following convention:
Učestalost nuspojava je određena sukladno sljedećim pravilima:
The frequency of possible adverse reactions listed below is defined using the following convention:
Učestalost mogućih nuspojava navedenih u nastavku definirana je koristeći sljedeće načelo:
The frequency of possible side effects listed below is defined as follows: Very common (may affect more than 1 patient in 10)
Učestalost mogućih nuspojava navedenih u nastavku određena je na sljedeći način: vrlo često (mogu se javiti u više od 1 na 10 bolesnika)
The frequency of possible side effects listed below is defined using the following convention:
Učestalost mogućih nuspojava navedenih ispod definirana je koristeći se sljedećom konvencijom:
The frequency of possible side effects listed below is defined using the following convention:
Učestalost mogućih nuspojava navedenih u nastavku definirana je korištenjem sljedećih konvencija:
The frequency of possible side effects listed below is defined using the following convention: very common (affects more than 1 user in 10)
Učestalost mogućih nuspojava navedenih ispod, definirane su prema sljedećem dogovoru: vrlo često (pojavljuju se u više od 1 na 10 korisnika)
The frequency of possible side effects listed below is defined using the following convention: very common (affects more than 1 user in 10)
Učestalost mogućih nuspojava navedenih u nastavku određena je prema sljedećem ustaljenom pravilu: vrlo često (javlja se kod više od 1 korisnika na 10)
The frequency of possible side effects listed below is defined using the following convention: very common (affects more than 1 user in 10)
Učestalost mogućih, dolje navedenih nuspojava definirana je kako slijedi: vrlo često (javlja se u više od 1 na 10 korisnika)
The frequency of Preotact dosing should be changed to 100 micrograms every other day
Učestalost primjene Preotacta treba promijeniti na 100 mikrograma svaki drugi dan
The frequency of serious infections among Humira treated subjects over 65 years of age (3.7%) was higher than for those under 65 years of age (1.5%).
Učestalost ozbiljnih infekcija među bolesnicima liječenima lijekom Humira veća je u osoba starijih od 65 godina (3,7%) nego u osoba mlađih od 65 godina (1,5%).
The frequency of side effects is defined by the following convention: very common (≥1/10), common (≥1/100 to ≤1/10), uncommon (≥1/1,000 to ≤1/100), rare (≥1/10,000 to ≤1/1,000), very rare (≤1/10,000), and not known (cannot be estimated from the available data).
Učestalost nuspojava definirana je sljedećom konvencijom: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000) i nepoznato (ne može se utvrditi iz dostupnih podataka).
The frequency of side effects listed below is defined using the following convention: Very common (may affect more than 1 in 10 people)
Učestalost mogućih nuspojava navedenih u daljnjem tekstu definira se na sljedeći način: Vrlo često (mogu se javiti u više od 1 na 10 osoba)
The frequency of tachycardia was 1.2% in patients receiving Betmiga 50 mg.
Učestalost tahikardije bila je 1,2% kod bolesnika koji su primali 50 mg lijeka Betmiga.
The frequency of the adverse drug reactions described below is based on data of one double blind controlled clinical trial involving 481 patients with MDR-TB, in which 321 patients received delamanid in combination with an Optimised Background Regimen (OBR).
Učestalost u nastavku opisanih nuspojava na lijek temelji se na podacima iz jednog kontroliranog dvostruko slijepog kliničkog ispitivanja koje je uključilo 481 bolesnika s MDR-TB, u kojem je 321 bolesnik primio delamanid u kombinaciji s optimiziranim osnovnim režimom liječenja (OBR, engl.
The frequency of the following side effects is not known (frequency cannot be estimated from the available data).
Učestalost sljedećih nuspojava nije poznata (učestalost se ne moţe procijeniti iz dostupnih podataka).
The frequency of the following side effects is not known (frequency cannot be estimated from the available data):
Učestalost sljedećih nuspojava nije poznata (učestalost se ne može procijeniti iz dostupnih podataka):
The frequency of the side effects listed below is defined using the following convention: Common: may affect up to 1 in 10 people
Učestalost dolje navedenih nuspojava definirana je na sljedeći način: Često: mogu se javiti u manje od 1 na 10 osoba
The frequency of the side effects listed below is defined using the following convention: Very common: may affect more than 1 in 10 people
Učestalost dolje navedenih nuspojava definirana je na sljedeći način: vrlo često: mogu se javiti u više od 1 na 10 osoba
The frequency of the side effects listed below is defined using the following definitions: Very common: may affect more than 1 in 10 people
Učestalost nuspojava navedenih u nastavku definirana je prema sljedećim kriterijima: Vrlo često: mogu se javiti u više od 1 na 10 osoba
The frequency of these adverse events is qualified as "not known".
Učestalost ovih štetnih događaja kategorizirana je kao "nepoznata".
The frequency of these adverse reactions reported from post-marketing experience cannot be estimated.
Učestalost tih nuspojava prijavljenih iz razdoblja nakon stavljanja lijeka u promet ne može se odrediti.
The frequency of these reactions is considered not known (cannot be estimated from the available data).
Učestalost ovih nuspojava smatra se nepoznatom (ne može se procijeniti iz dostupnih podataka).
The frequency of this is unknown (see section 4.4).
Učestalost ove nuspojave nije poznata (vidjeti dio 4.4)
The frequency of urinary tract infections was 2.9% in patients receiving Betmiga 50 mg.
Učestalost infekcija urinarnog trakta bila je 2,9% kod bolesnika koji su primali 50 mg lijeka Betmiga.
The frequency of volume depletion events was increased in patients 75 years and older treated with empagliflozin 10 mg (2.3%) or empagliflozin 25 mg (4.4%) compared to placebo (2.1%).
Učestalost događaja deplecije volumena je bila povećana u bolesnika u dobi 75 ili više godina, koji su liječeni empagliflozinom od 10 mg (2,3%) ili empagliflozinom od 25 mg (4,4%) u usporedbi s placebom (2,1%).
The frequency rate of the side effects associated with INTELENCE is given below.
Stopa učestalosti nuspojava povezanih s INTELENCEom navedena je niže.
The frequency terms listed are defined as follows: Very common (≥ 1/10 ), common (≥ 1/100 to< 1/10).
Navedene učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10%), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1 000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1 000), vrlo rijetko (< 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 < 1/100), rare (≥ 1/10,000 to< 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 and < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1 000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1 000), vrlo rijetko (< 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to
Navedene učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥ 1/100 to < 1/10 %), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000% and < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1 000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1 000), vrlo rijetko (< 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
The frequency, type and severity of adverse drug reactions in paediatric patients were comparable to those observed in adults.
Učestalost, vrsta i težina nuspojava u pedijatrijskih bolesnika bili su usporedivi s onima primijećenima u odraslih.
The frequency, type and severity of adverse reactions in the paediatric population do not indicate differences to the experience in the general diabetes population (see section 5.1).
Učestalost, vrsta i težina nuspojava u pedijatrijskoj populaciji ne upućuju na razlike u odnosu na iskustvo u općoj populaciji oboljelih od šećerne bolesti (vidjeti dio 5.1).
The frequency, type and severity of adverse reactions in the paediatric population do not indicate differences to the experience in the general diabetes population with the exception of a signal of higher occurrence of severe hypoglycaemia compared to a basal- bolus regimen in paediatric population, particularly in children 2 to 5 years old (see section 4.2, 4.4 and 5.1).
Učestalost, vrsta i težina nuspojava u pedijatrijskoj populaciji ne upućuju na razlike u odnosu na iskustvo u općoj populaciji bolesnika sa šećernom bolešću, osim signala češće pojave teške hipoglikemije u odnosu na bazal-bolus režim u pedijatrijskoj populaciji, osobito u djece u dobi od 2 do 5 godina (vidjeti dijelove 4.2, 4.4 i 5.1).
the front of the thighs, the abdomen, except for the area around the navel.
prednji dio bedra, trbuh, osim područja oko pupka.
the front of your thigh your abdomen, except for the 5 cm area around the navel (Figure 3).
prednji dio bedra trbuh, osim područja od 5 cm oko pupka (Slika 3).
The frontal lobes and anterior cingulate (f, ac, axial review)
Frontalne režnjeve i prednji cingulatni režanj (f, ac, aksijalni prikaz)
The frozen pre-filled syringes can be thawed and then refrigerated for future use.
Zamrznuta napunjena štrcaljka može se otopiti i zatim ponovno pohraniti u hladnjaku za buduću primjenu.
The full analysis population included 343 patients with ALK-positive advanced NSCLC as identified by Fluorescence In Situ Hybridization (FISH) prior to randomisation: 172 patients were randomised to crizotinib and 171 patients were randomised to chemotherapy (pemetrexed + carboplatin or cisplatin; up to 6 cycles of treatment).
Potpuna analiza populacije uključivala je 343 bolesnika s ALK-pozitivnim uznapredovalim NSCLC- om, kako je utvrđeno testom fluorescentne in situ hibridizacije (FISH) prije randomizacije: 172 bolesnika bila su randomizirana u skupinu krizotiniba, a 171 bolesnik u kemoterapijsku skupinu (pemetreksed + karboplatin ili cisplatin; do 6 ciklusa liječenja).
The full analysis population included 347 patients with ALK-positive advanced NSCLC as identified by FISH prior to randomisation.
Potpuna analiza populacije uključivala je 347 bolesnika s ALK-pozitivnim uznapredovalim NSCLC- om, kako je utvrđeno testom fluorescentne in situ hibridizacije (FISH) prije randomizacije.
The Full Analysis Set (FAS) consisted of all randomized subjects (N=98) who received at least one dose of any study medicine (peginterferon alfa–2b, ribavirin, or Victrelis).
Cijeli set analiza (FAS) obuhvaćao je sve randomizirane ispitanike (N= 98) koji su primili barem jednu dozu bilo kojeg studijskog lijeka (peginterferona alfa-2b, ribavirina ili lijeka Victrelis).
The Full Analysis Set population included men regardless of baseline HPV status at Day 1, who received at least one vaccination and in whom case counting started at Day 1.
Analiza cjelokupne uključene populacije uključivala je muškarce bez obzira na njihov početni HPV status 1-og dana ispitivanja, koji su primili barem jednu dozu cjepiva i u kojih je računanje započelo 1- og dana.
The full contents of each sachet should be mixed with at least 30 ml of liquid (water, milk, fruit juice), or 3 tablespoons of semi-solid food (yogurt or applesauce).
Cjelokupan sadržaj svake vrećice treba pomiješati s najmanje 30 ml tekućine (vode, mlijeka, voćnoga soka) ili 3 jušne žlice polukrute hrane (jogurta ili gustog soka od jabuke).
The full contents of each sachet should be mixed with at least 30 ml of liquid (water, milk, fruit juice), or 3 tablespoons of semi-solid food (yogurt or applesauce).
Puni sadržaj svake vrećice treba pomiješati s najmanje 30 ml tekućine (vode, mlijeka, voćnoga soka) ili 3 jušne žlice polukrute hrane (jogurta ili gustog soka od jabuke).
The full effect of Picato can be evaluated approximately 8 weeks after treatment.
Potpuni učinak lijeka Picato može se procijeniti otprilike 8 tjedana nakon liječenja.
The full EPAR and risk management plan summary for Abasaglar can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Abasaglarnalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Accofil can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Accofil nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Adempas can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) kao i plan upravljanja rizikom za lijek Adempas nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.